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Breast cancer is one of the most important health problems among females. One of
the most important challenges regarding breast cancer diagnosis and treatment is the
precise clinical staging of the disease. With regards to the selection of appropriate
treatment method, identifying the lymph node involvement by cancerous cells is a
major determinant. Until now, many attempts have been made to find stage specific
molecular markers to help the clinicians make precise staging of the disease.
Through this, evaluating the activity of some important genes in cancer evolution and
progression seems to be the most sensible step in this direction.
p53, Cyclin E and Rb are genes that are mostly interactive in cell cycle regulation
and cell division as well, has been shown to have an important role in cancer
development particularly in breast cancer. Abnormalities in their inhibitory and or
stimulatory roles in cell cycle progression can lead cells to enter hyperproliferative or
neoplastic states. Therefore, assessments to determine their activity can lead to
finding any differences in their expression levels between benign and malignant
breast tissues, as well as different stages of breast cancer.
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In the present study we have used Reversed Transcriptase in situ Polymerase Chain
Reaction (RT in situ PCR) in order to determine p53, Cyclin E and Rb mRNA
expressions in different human breast samples including benign and malignant
tissues. This method allows detection of very low copies ofmRNA at cellular level.
In the current study, the presence of p53, Cyclin E and Rb mRNA expressions were
investigated in 17 cases of human breast tissues, which were donated as paraffin
embedded materials by the pathology ward of Milad hospital, located in Tehran, Iran.
We divided the samples into four groups based on their pathology reports. Five
samples in each first group as named; non-malignant human breast lesions or NM,
lymph node negative human breast cancer (No regional lymph node involvement;
LNN) and lymph node positive human breast cancer (Positive for regional lymph
node involvement; LNP). There were just two samples available in the fourth group
of our study as extra nodal metastatic human breast cancer (Positive for distant
metastasis; MB).
Our data analysis was mostly based on qualitative assessment of the images which
includes the presence of expression in tissue sections as well as the location of the
signals throughout the tissue and inside the cells. In addition, we did statistical
analysis to compare the abundance of expression among different categories of our
samples. Analysis of the data showed that the closest results to significant level
«0.05) were those comparing benign and malignant groups especially for Rb
.
mRNA. While, the most improbable results to significant level were those comparing
among four study groups especially between LNP and MB.
IV
PERPUSTAKAAN PBRUBATAN &; sAINS KBSlHATAN
UNIVERSm PUTRA MALAYSlA
Our findings demonstrated a dominant presence of p53 and Cyclin E mRNA
expression in malignant breast tissues as compared to benign lesions. On the
contrary_ benign breast lesions showed a more dominant expression of Rb mRNA
than malignant tissues.
A companson between different breast cancer groups in our study showed slight
differences in the proportions and intensities of p53, Cyclin E and RB mRNA
expreSSIOns. These differences could be meaningful but the nature of our study,
which was a qualitative method of research, does not allow definitive inference from
the findings.
In conclusion, RT in silu PCR as a qualitative method is able to localize mRNA gene
expression in human breast lesions. In addition, mRNA expression levels are
obviously different in benign tissues compared to malignant tissues. However, it is
not possible to rely on the light differences between three malignant groups of our
study. It is therefore necessary to do further investigations with quantitative research
methods such as microarray analysis and or quantitative RT- PCR.
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Perubatan dan Sains Kesihatan
Kanser payudara adalah masalah kesihatan yang paling utama yang dihidapi oleh
golongan wanita. Salah satu cabaran utama dalam mendiagnosa dan pengubatan
kanser payudara adalah dalam kepersisan dalam mengkelasifikasikan peringkat-
peringkat kanser. Dalam pemilihan cara pengubatan yang paling bersesuaian,
pengenalpastian kalenjar limfa yang terlibat juga merupakan salah satu cara yang
utama. Sehingga sekarang, pelbagai cubaan telah dijalankan untuk mencari marker
molecular spesifik dengan tujuan untuk membantu para pakar surgen dan Perubatan
kedal dan Qulcologia untuk membuat keputusan tepat mengenai peringkat-peringkat
kanser payudara. Melaluinya, penilaian aktiviti sesetengah gen penting di dalam
evolusi dan perkembangan kanser didapati penting didalam pemilihan jenis rawatan
kanser berkenaan.
p53, Cyclin E dan Rb adalah gen yang terlibat dalam kitaran dan pembahagian sel,
telah dibukti memainkan peranan penting dalam pembentukan kanser, terutamanya
kanser payudara. Ketidaknormalan peranan gen tersebut di dalam proses menyekat
.
dan/atau mencetus perkembangan kitaran sel boleh menyebabkan sel memasuki
peringkat hiperpoliferasi malahan neoplastik. Oleh itu, penilaian aktiviti gen tersebut
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boleh membawa kepada penemuan sebarang perbezaan tahap ekpresi di antara
benigna dan malignan, termasuk peringkat-peringkat kanser payudara.
Di dalam kajian ini, kami telah menggunakan Reversed Transcriptase in situ
Polymerase Chain Reaction (RT in situ PCR) untuk menentukan ekpresi p53, Cyelin
E dan Rb mRNA dalam sampel payudara manusia yang berbeza termasuklah tisu
benigna dan malignan. Kaedah ini membolehkan jumlah mRNA yang sangat rendah
pada peringkat sel dikenalpasti.
Kami telah mengkaji kehadiran ekpresi p53, Cyelin E dan Rb mRNA dalam 17 kes
tisu payudara manusia yang tertanam dalam "paraffin" yang didermakan oleh wad
patologi Hospital Milad yang terletak di Tehran, Iran.
Kami telah membahagikan sampel kepada empat kumpulan berdasarkan laporan
patologi. Lima sampel di dalam setiap kumpulan; lesi keabnormalan payudara
manusia benigna, kanser payudara manusia negatif nodus limfa dan kanser payudara
manusia positif nodus limfa. Hanya terdapat dua sampel dalam kumpulan keempat
kajian kami sebagai kanser payudara manusia metastatik.
Perbandingan di antara kumpulan-kumpulan kanser payudara dalam kajian kami
menunjukan sedikit perbezaan nisbah dan kekuatan ekpresi p53, Cyelin E dan Rb
mRNA. Walaupun perbezaan ini boleh digunapakai, tetapi adalah berkemungkinan
ianya tidak tepat kerana kami menggunakan kaedah kualitatif dan sampel yang
terhad.
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Kesimpulannya, RT in situ PCR adalah kaedah kualitatif yang boleh mengenalpasti
lokasi ekpresi gen mRNA dalam tisu payudara manusia. Tambahan pula, tahap
ekpresi mRNA adalah nyata berbeza di antara tisu benign berbanding dengan tisu
malignan. Bagi membolehkan perbezaan yang sedikit di antara tiga kumpulan
malignan dalam kajian kami diambil kira, adalah perlu untuk melakukan kajian yang
lebih mendalam termasuk kaedah kajian kuantitatif seperti analisis microarray
danlatau quantitative RT-PCR.
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CHAPTER 1
INTRODUCTION
Breast cancer is a great problem of human's and especially women's health at the
present time. It is diagnosed one million times every year worldwide (Berns el af.
2004). It is the second leading cause of cancer deaths in women today (after lung
cancer) and the most common cancer among women, excluding nonmelanoma skin
cancers. In Iran, breast cancer continues to increase in numbers yearly and remains
an imp0l1ant health problem, although its statistics is very similar to that of other
countries in the region (Harirchi et af. 2002).
One of the most important issues in improving health indices regarding breast cancer
is using individualized treatment methods. Strategies for treatment in breast cancer
depends on the extent of disease progression in the body that will be evaluated by
certain criteria; size of the tumor mass, lymph node involvement and the presence of
metastasis which is based on TNM system (T; tumor size, N; lymph node
involvement and M; metastasis). In order to help the clinicians to decide on treatment
modalities, it is necessary to have a standard method for determining disease
progression. Breast cancer is usually divided into four stages based on above criteria.
There are different prognoses, choices of treatment, response rates to therapy and
survival in each of different stages of breast cancer. In order to use targeted therapy
clinicians need to know the precise stage of a breast cancer, which determines the
extent of disease
